Literature DB >> 28787275

Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research.

Tomasz Grzegorski1, Jacek Losy1.   

Abstract

Multiple sclerosis (MS) is a chronic, progressive disease of the central nervous system that is characterised by inflammatory damage to the myelin sheath. Though often neglected, cognitive impairment is a common feature of MS that affects 43-70% of patients. It has a sophisticated neuroanatomic and pathophysiologic background and disturbs such vital cognitive domains as speed of information processing, memory, attention, executive functions and visual perceptual functions. In recent years there has been growing interest in neuroimaging findings with regard to cognitive impairment in MS. The possible options of managing cognitive dysfunction in MS are pharmacologic interventions, cognitive rehabilitation and exercise training; however, not enough evidence has been presented in this field. The aim of our article is to provide current knowledge on cognitive impairment in MS based on the most recent scientific results and conclusions with regard to affected cognitive domains, neuropsychological assessment, underlying mechanisms of this disturbance, neuroimaging findings and therapeutic options.

Entities:  

Keywords:  cognitive dysfunction; executive functions; memory; neuroimaging; neuropsychological assessment

Mesh:

Year:  2017        PMID: 28787275     DOI: 10.1515/revneuro-2017-0011

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  30 in total

1.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

2.  A Simple Computational Approach to Identify Potential Drugs for Multiple Sclerosis and Cognitive Disorders from Expert Curated Resources.

Authors:  Kalpana Raja; Archana Prabahar; Shyam Sundar Arputhanatham
Journal:  Methods Mol Biol       Date:  2022

3.  Memory in multiple sclerosis: A reappraisal using the item specific deficit approach.

Authors:  Michael R Basso; Douglas Whiteside; Dennis Combs; Steven Paul Woods; Jordan Hoffmeister; Ryan Mulligan; Peter Arnett; Eva Alden; Oliver Tobin
Journal:  Neuropsychology       Date:  2021-02       Impact factor: 3.295

4.  Variables Associated with Self-reported Language Impairment in Multiple Sclerosis: A Regression Analysis.

Authors:  Sarah El-Wahsh; Rob Heard; Hans Bogaardt; Fiona Kumfor; Kirrie J Ballard
Journal:  Int J MS Care       Date:  2021-04-14

Review 5.  Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review.

Authors:  Riley Bove; Annette Okai; Maria Houtchens; Birte Elias-Hamp; Alessandra Lugaresi; Kerstin Hellwig; Eva Kubala Havrdová
Journal:  Front Neurol       Date:  2021-03-19       Impact factor: 4.003

6.  Cognitive and Central Vestibular Functions Correlate in People With Multiple Sclerosis.

Authors:  Graham D Cochrane; Jennifer B Christy; Brian M Sandroff; Robert W Motl
Journal:  Neurorehabil Neural Repair       Date:  2021-09-24       Impact factor: 3.919

7.  Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.

Authors:  Mini Singh; Ronald Gavidia; Galit Levi Dunietz; Elizabeth Washnock-Schmid; Andrew R Romeo; Shelley Hershner; Ronald D Chervin; Tiffany J Braley
Journal:  Mult Scler       Date:  2021-05-28       Impact factor: 6.312

8.  Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.

Authors:  Jessica Podda; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto
Journal:  Mult Scler       Date:  2020-10-13       Impact factor: 5.855

9.  Serum insulin-like growth factor 1 (IGF-1) in multiple sclerosis: relation to cognitive impairment and fatigue.

Authors:  Rania S Nageeb; Noha A Hashim; Amal Fawzy
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-09-15

Review 10.  Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Authors:  Serena Brancati; Lucia Gozzo; Laura Longo; Daniela Cristina Vitale; Filippo Drago
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.